Supply Chain Archives
07/22/2025
What’s Next for the CGT Industry? Mid-Year Check-In from the Leadership Team
We’re halfway through 2025, and the cell and gene therapy (CGT) landscape stands at a crossroads. Innovation continues to advance, yet the infrastructure required to support commercialization remains under pressure. To assess the current state of the industry and what’s ahead, Cryoport Systems gathered candid insights from our internal leaders across functions, from product development and commercial strategy to operations and client engagement.
06/28/2025
Celebrating Logistics, the Unsung Hero in Cell and Gene Therapy Innovation
Every National Logistics Day offers a chance to recognize the systems and people that quietly power the innovation engine for Cell and Gene Therapy (CGT). While logistics frequently brings to mind images of trucks and warehouses, cardboard boxes, and tracking numbers, for CGT developers, it’s the infrastructure that protects innovation and ensures that time-sensitive, potentially life-changing treatments reach patients intact and on time. At Cryoport Systems, logistics has never been just about transportation. It’s about Enabling the Outcome™.
06/27/2025
Bridging the Gaps: How Cryoshuttle® Enhances First and Last Mile Resilience
For advanced therapies, the most vulnerable parts of the transportation journey aren’t always the longest. In fact, the greatest risks often occur in the shortest distances. While intercontinental transport and customs clearance are well-known hurdles, both the first and last mile remain highly vulnerable to disruption. Cryoport Systems developed our Cryoshuttle® local pickup and delivery services to help close the gap between global transport lanes and local handling environments.
06/17/2025
Ensuring Safe, On-Time Deliveries for Animal Biopharma
Transporting advanced therapeutics for the animal health industry is just as time- and temperature-sensitive as human therapeutics, yet it is not often managed with the same level of care. This results in biologics and vaccines running into preventable risk during transit. Whether you’re supporting a clinical trial, delivering commercial supply, or responding to a health emergency, ensuring the quality, compliance, and visibility of every shipment is crucial.
06/04/2025
Engineering for Impact: A Conversation with Mike Dybicz on the HV3 and Safepak Systems
When it comes to cell and gene therapy (CGT) logistics, innovation is about more than improving efficiency, it’s about safeguarding a patient’s only chance at treatment. We sat down with Mike Dybicz, Senior Vice President & Chief Product Development Officer, to discuss how Cryoport Systems is reshaping the future of CGT logistics with innovative products such as Cryoport Express® Cryogenic HV3 Shipping System and Safepak® System 1800, designed specifically to reduce risk, increase reliability, and ultimately improve patient outcomes.
06/01/2025
Honoring Survivors, Enabling the Future
Each year on the first Sunday in June, National Cancer Survivors Day serves as a powerful reminder that behind every innovation in medicine, every breakthrough treatment, and every clinical milestone, there are human stories of courage, resilience, and hope. At Cryoport Systems, we pause today not only to recognize the strength of cancer survivors but also to reflect on how our work supports the treatments that are changing survival outcomes.
05/29/2025
Starting Smart: How to Structure an Integrated Supply Chain in Early-Stage CGT Programs
For many academic labs, technology spinouts, and early-stage CGT companies, the temperature-controlled supply chain feels like something to figure out later. But when dealing with highly sensitive starting materials and therapies like CGTs, later can quickly become too late. Whether you’re preparing for first-in-human trials or just beginning to plan for scale, integrated thinking now can spare you time, cost, and complexity later.
05/20/2025
Why Animal Health Supply Chains Require Uncompromising Quality
Quality failures in animal health logistics do more than delay delivery, they put animal welfare at risk, threaten product efficacy, and erode public trust in veterinary medicine. Today’s biologics and vaccines are often made with temperature-sensitive proteins, viral vectors, or living cells, making the cold chain a essential operational function that directly impacts both clinical outcomes and commercial success.
04/16/2025
